Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update

Canadian Journal of Diabetes

Volumn 40, Issue 3, 2016, Pages 193-195

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; EMPAGLIFLOZIN; HEMOGLOBIN A1C; LIXISENATIDE; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG TOLERABILITY; HIGH RISK POPULATION; HUMAN; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRACTICE GUIDELINE; RISK REDUCTION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; CANADA; DIABETES MELLITUS, TYPE 2;

CANADA; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; TREATMENT OUTCOME;

EID: 84979929984     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2016.02.006     Document Type: Note

References (20)

1. 1 Booth, G., Cheng, A.Y.Y., Canadian diabetes association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada: Methods. Can J Diabetes 37:Suppl. 1 (2013), S4–7.
2. 2 White, W.B., Cannon, C.P., Heller, S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
3. 3 Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
4. 4 Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
5. 5 Pfeffer, M.A., Claggett, B., Diaz, R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
6. 6 Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
7. 7 Smith, N., Barzilay, J., Kronmal, R., et al. New-onset diabetes and risk of all-cause and cardiovascular mortality. Diabetes Care 29 (2006), 2012–2017.
8. 8 Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
9. 9 Neal, B., Perkovic, V., de Zeeuw, D., et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS); A randomized placebo-controlled trial. Am Heart J 166 (2013), 217–223 e11.
10. 10 Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58). study record detail (updated December 10 https://www.clinicaltrials.gov/ct2/show/NCT01730534?term=DECLARE&rank=2, 2015 Accessed November 1, 2015.
11. 11 The ORIGIN Trial Investigators, Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367 (2012), 319–328.
12. 12 Dormandy, J., Charbonnel, B., Eckland, D., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspectivepioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366 (2005), 1279–1289.
13. 13 Home, P.D., Pocock, S.J., Beck-Nielsen, H., et al., for the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet 373 (2009), 2125–2135.
14. 14 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
15. 15 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998), 854–865.
16. 16 Holman, R.R., Paul, S.K., Bethel, M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
17. 17 Sumeet, R., Singh, S.R., Ahmad, F., et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: A meta-analysis. CMAJ 180 (2009), 385–397.
18. 18 Horvath, K., Jeitler, K., Berghold, A., et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus (review). Cochrane Database Syst Rev(2), 2007 CD005613.
19. 19 Monami, M., Marchionni, N., Mannucci, E., Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: A meta-analysis. Diabetes Res Clin Pract 81 (2008), 184–189.
20. 20 Manucci, E., Monami, M., Marchionni, N., Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: A meta-analysis. Diabetes Obes Metab 11 (2009), 53–59.